Patents by Inventor Dimiter S. Dimitrov

Dimiter S. Dimitrov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human monoclonal antibodies specific for CD22
    Patent number: 10494435
    Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: December 3, 2019
    Assignee: The Government of the United States America as represented by the Secretary of the Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Xiaodong Xiao, Ira H. Pastan
  • HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR FLT3 AND USES THEREOF
    Publication number: 20190352408
    Abstract: Human monoclonal antibodies that specifically bind Fms-like tyrosine kinase 3 (FLT3) are described. Chimeric antigen receptors (CARs) and other antibody conjugates that include the FLT3-specific monoclonal antibodies are also described. Methods for the diagnosis and treatment of FLT3-associated cancer, such as acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML), are further described.
    Type: Application
    Filed: December 21, 2017
    Publication date: November 21, 2019
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Terry J. Fry, Christopher Chien
  • Bispecific multivalent fusion proteins
    Patent number: 10472412
    Abstract: The invention provides a construct comprising two or more fusion proteins of Formulas (I)-(IV): A-(optional linker)-C-(optional linker)-B (Formula I), B-(optional linker)-D-(optional linker)-E-(optional linker)-B (Formula II), A-(optional linker)-C (Formula III), and B-(optional linker)-D-(optional linker)-E (Formula IV), wherein A denotes an antibody or antibody fragment, B denotes a single domain CD4, C denotes an immunoglobulin light chain constant region D denotes an immunoglobulin heavy chain constant region, and E denotes an Fc region or a portion thereof that is optionally defucosylated.
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 12, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Fudan University
    Inventors: Dimiter S. Dimitrov, Weizao Chen, Tianlei Ying
  • Compositions and methods for treating cancer with anti-CD33 immunotherapy
    Patent number: 10426797
    Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: October 1, 2019
    Assignees: LENTIGEN TECHNOLOGY, INC., United States of America as Represented by the Secretary, The Dept. of Health and Human Services
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-ROR1 immunotherapy
    Patent number: 10428141
    Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: October 1, 2019
    Assignees: LENTIGEN TECHNOLOGY, INC., The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Human monoclonal antibodies against the middle east respiratory syndrome coronavirus (MERS-CoV) and engineered bispecific fusions with inhibitory peptides
    Patent number: 10421802
    Abstract: The invention provides polypeptides (e.g., antibodies) and fusion proteins that target a epitope in the receptor binding domain (RBD) of the spike (S) glycoprotein of the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The polypeptides and fusion proteins can be used to treat and prevent MERS-CoV infection in mammals.
    Type: Grant
    Filed: October 16, 2014
    Date of Patent: September 24, 2019
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Veritech Limited
    Inventors: Dimiter S. Dimitrov, Tianlei Ying, Tina W. Ju, Kwok Yung Yuen
  • Engineered antibody constant domain molecules
    Patent number: 10358481
    Abstract: Described herein are engineered antibody constant domain molecules, such as CH2 or CH3 domain molecules, comprising at least one mutation, or comprising at least one complementarity determining region (CDR), or a functional fragment thereof, engrafted in a loop region of the CH2 domain. The CH2 domain molecules described herein are small, stable, soluble, exhibit little to no toxicity and are capable of binding antigen.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 23, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Dimiter S. Dimitrov
  • Compositions and Methods for Treating Cancer with Anti-Mesothelin Immunotherapy
    Publication number: 20190218280
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 18, 2019
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Anti-HIV domain antibodies and method of making and using same
    Patent number: 10287340
    Abstract: The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.
    Type: Grant
    Filed: September 28, 2015
    Date of Patent: May 14, 2019
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Dimiter S. Dimitrov, Weizao Chen
  • Compositions and Methods For Treating Cancer With Anti-CD19 Immunotherapy
    Publication number: 20190106492
    Abstract: Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 11, 2019
    Inventors: Dina Schneider, Rimas J. Orentas, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods For Treating Cancer With Anti-CD22 Immunotherapy
    Publication number: 20190099476
    Abstract: Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
    Type: Application
    Filed: October 16, 2018
    Publication date: April 4, 2019
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • M971 CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20190085078
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Application
    Filed: August 21, 2018
    Publication date: March 21, 2019
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
  • Compositions and Methods for Treating Cancer with Anti-ROR1 Immunotherapy
    Publication number: 20190055309
    Abstract: Chimeric antigen receptors containing ROR1 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: November 2, 2018
    Publication date: February 21, 2019
    Inventors: Rimas J. Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and methods for treating cancer with anti-mesothelin immunotherapy
    Patent number: 10183993
    Abstract: Chimeric antigen receptors containing mesothelin antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Grant
    Filed: January 9, 2018
    Date of Patent: January 22, 2019
    Assignee: Lentigen Technology Inc.
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • MONOCLONAL ANTIBODIES SPECIFIC FOR FIBROBLAST GROWTH FACTOR RECEPTOR 4 (FGFR4) AND METHODS OF THEIR USE
    Publication number: 20180318440
    Abstract: Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
    Type: Application
    Filed: September 19, 2016
    Publication date: November 8, 2018
    Applicant: The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Javed Khan, Sivasubramanian Baskar, Rimas J. Orentas, Dimiter S. Dimitrov, Zhongyu Zhu
  • Compositions and Methods for Treating Cancer with Anti-CD33 Immunotherapy
    Publication number: 20180280438
    Abstract: Chimeric antigen receptors containing CD33 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
    Type: Application
    Filed: March 23, 2018
    Publication date: October 4, 2018
    Inventors: Rimas Orentas, Dina Schneider, Boro Dropulic, Dimiter S. Dimitrov, Zhongyu Zhu
  • M971 chimeric antigen receptors
    Patent number: 10072078
    Abstract: The invention provides a chimeric antigen receptor (CAR) comprising an antigen binding domain comprising SEQ ID NOs: 1-6, a transmembrane domain, and an intracellular T cell signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal are also disclosed.
    Type: Grant
    Filed: September 18, 2013
    Date of Patent: September 11, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Rimas J. Orentas, Ira H. Pastan, Dimiter S. Dimitrov, Crystal L. Mackall
  • ANTI-HUMAN FOLATE RECEPTOR BETA ANTIBODIES AND METHODS OF USE
    Publication number: 20180251544
    Abstract: Human anti-human folate receptor beta antibodies and antigen-binding fragments thereof are described, as well as method of using such antibodies and fragments to treat inflammatory disorders or cancers expressing cell surface FR?.
    Type: Application
    Filed: May 3, 2018
    Publication date: September 6, 2018
    Applicants: PURDUE RESEARCH FOUNDATION, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY DEPARTMENT OF HE
    Inventors: Philip S. LOW, Dimiter S. DIMITROV, Yang FENG, Jiayin SHEN
  • MESOTHELIN-TARGETED CHIMERIC ANTIGEN RECEPTORS AND USES THEREOF
    Publication number: 20180251546
    Abstract: The presently disclosed subject matter provides for methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to chimeric antigen receptors (CARs) that specifically target human mesothelin, and immunoresponsive cells comprising such CARs. The presently disclosed mesothelin-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 6, 2018
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, The U.S.A. as Represented by the Secretary, Department Of Health and Human Services
    Inventors: Prasad S. Adusumilli, Michel Sadelain, Dimiter S. Dimitrov, Yang Feng
  • ANTIGEN-BINDING PROTEINS TARGETING CD56 AND USES THEREOF
    Publication number: 20180230214
    Abstract: The presently disclosed subject matter provides for methods and compositions for treating cancer (e.g., multiple myeloma). It relates to anti-CD56 antibodies, chimeric antigen receptors (CARs) that specifically target human CD56, and immunoresponsive cells comprising such CARs. The presently disclosed CD56-specific CARs have enhanced immune-activating properties, including anti-tumor activity.
    Type: Application
    Filed: January 31, 2018
    Publication date: August 16, 2018
    Applicants: MEMORIAL SLOAN-KETTERING CANCER CENTER, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HE
    Inventors: Michel Sadelain, Reuben Benjamin, Dimiter S. Dimitrov, Yang Feng